Equity Profile

APLS

Apellis Pharmaceuticals, Inc.

Health CareBiotechnology$5.3B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:56 AM EDT

Apellis Pharmaceuticals Beats on EPS, Stock Down 0.27%

Metric	Actual	Expected	Surprise
EPS	$0.15	$-0.36	+139.27%
Revenue	—	$203M	—

management commentary, guidance changes, and full analysis available with Pro.

Apellis Pharmaceuticals Beats on EPS, Stock Down 0.27%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.15	$-0.36	+139.27%
Revenue	—	$203M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Apellis Pharmaceuticals reported a significant earnings surprise with an EPS of $0.15, compared to the expected loss. However, the stock reacted negatively, declining by 0.27%. The lack of revenue figures and guidance may have contributed to investor uncertainty.

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

$-0.36

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$203M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. Operating in the health care sector, it aims to address significant unmet medical needs, particularly in autoimmune and hematologic disorders.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In the last quarter, Apellis reported an EPS of $0.47, significantly beating expectations. However, the stock price fell the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to advancing clinical trials.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts expect Apellis to report a loss this quarter, but there is hope for revenue growth as the company continues to launch new products.

Bull Case

If Apellis can exceed revenue expectations and show a path to profitability, it could boost investor confidence and drive the stock higher.

Bear Case

If the company fails to meet revenue estimates or reports wider losses, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.36

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

Revenue

$203M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will revenue exceed the consensus estimate of $203M?

Revenue performance is critical for assessing the company's growth trajectory and market acceptance of its products.

What specific plans does management have to reduce losses this quarter?

Understanding management's strategy for improving profitability will be key for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by recent product launches, which could lead to a stronger performance than expected.

Supporting Evidence

The company has a history of beating EPS estimates, which could translate to better-than-expected revenue.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.

Key Risk

If revenue comes in above $203M, it could shift investor sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for revenue growth against the backdrop of ongoing losses, making this quarter's performance critical.

Bull Confirmed If

Revenue growth exceeding $203M with a clear path to reducing losses.

Bear Confirmed If

Revenue falling below $170M or wider losses than expected.

Pre-Earnings Positioning

Options Market

Implied Move

±5.72%

Historical Avg

±8.8%

Pricing cheap

The options market is pricing in a moderate move around the earnings report, suggesting uncertainty about the results.

Options are pricing ±1.2% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

248.4%

Calls (7K)P/C Ratio: 0.12Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests the stock could rise by around 10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around 3.8%, reflecting ongoing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product launches and their market reception.
2Any commentary on cost management strategies.
3Details on ongoing clinical trials and their timelines.
4Insights into competitive positioning in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

AXSMReported

Axsome Therapeutics, Inc.

RecapView

May4

KRYSReported

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

$-0.36

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$203M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In the last quarter, Apellis reported an EPS of $0.47, significantly beating expectations. However, the stock price fell the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to advancing clinical trials.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts expect Apellis to report a loss this quarter, but there is hope for revenue growth as the company continues to launch new products.

Bull Case

If Apellis can exceed revenue expectations and show a path to profitability, it could boost investor confidence and drive the stock higher.

Bear Case

If the company fails to meet revenue estimates or reports wider losses, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.36

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

Revenue

$203M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will revenue exceed the consensus estimate of $203M?

Revenue performance is critical for assessing the company's growth trajectory and market acceptance of its products.

What specific plans does management have to reduce losses this quarter?

Understanding management's strategy for improving profitability will be key for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by recent product launches, which could lead to a stronger performance than expected.

Supporting Evidence

The company has a history of beating EPS estimates, which could translate to better-than-expected revenue.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.

Key Risk

If revenue comes in above $203M, it could shift investor sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for revenue growth against the backdrop of ongoing losses, making this quarter's performance critical.

Bull Confirmed If

Revenue growth exceeding $203M with a clear path to reducing losses.

Bear Confirmed If

Revenue falling below $170M or wider losses than expected.

Pre-Earnings Positioning

Options Market

Implied Move

±5.72%

Historical Avg

±8.8%

Pricing cheap

The options market is pricing in a moderate move around the earnings report, suggesting uncertainty about the results.

Options are pricing ±1.2% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

248.4%

Calls (7K)P/C Ratio: 0.12Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests the stock could rise by around 10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around 3.8%, reflecting ongoing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product launches and their market reception.
2Any commentary on cost management strategies.
3Details on ongoing clinical trials and their timelines.
4Insights into competitive positioning in the biotechnology space.